Hypogonadism and metabolic syndrome

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Metabolic Health

Background:

• The interplay between metabolic syndrome (MetS) and male hypogonadism in cardiovascular (CV) risk stratification remains unclear.
• Understanding this relationship is crucial for accurate CV risk assessment in men.

Purpose of the Study:

• To review the association between testosterone (T) and MetS.
• To explore their potential interaction in the development of CV diseases.

Main Methods:

• A systematic literature search was conducted using Medline.
• The search covered publications from 1969 to January 2011.

Main Results:

• Subjects with MetS exhibit lower total testosterone (TT) levels, with hypogonadism more prevalent in those with erectile dysfunction (ED).
• Low T is associated with increased risk of developing MetS, and vice versa; increased waist circumference is a key factor in MetS-associated hypogonadism.
• Testosterone replacement therapy (TRT) may reduce visceral fat and improve insulin sensitivity, while androgen deprivation increases abdominal adiposity.

Conclusions:

• The clinical impact of MetS-associated hypogonadism requires further investigation.
• Clarification is needed on whether low T is a cause or consequence of MetS.
• Larger, longer-term studies are necessary to confirm the CV risk reduction benefits of TRT.